Last reviewed · How we verify
HALOPROGIN
Haloprogin, marketed by Westwood Squibb, is an antifungal agent indicated for the treatment of tinea corporis, competing in a class with several off-patent generics and one drug with an unknown patent status. Its unique mechanism of action, binding to the adenosine receptor A3 to inhibit fungal growth, sets it apart from other antifungals in the same class. The primary risk to Haloprogin's market position is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | HALOPROGIN |
|---|---|
| Sponsor | Westwood Squibb |
| Drug class | haloprogin |
| Target | Adenosine receptor A3 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Tinea corporis
- Tinea cruris
- Tinea pedis
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HALOPROGIN CI brief — competitive landscape report
- HALOPROGIN updates RSS · CI watch RSS
- Westwood Squibb portfolio CI